Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

AUTOR(ES)

Frommel, D

RESUMO

Partially purified antigens, derived from Leishmania infantum or L. major promastigotes and isolated under reducing conditions, were used to immunize BALB/c mice. Three subcutaneous injections of the 64- to 97-kilodalton preparation in conjunction with muramyl dipeptide conferred long-lasting immunity against L. mexicana subsp. mexicana and L. major infection; they led to the development of antibodies neutralizing the infectiousness of promastigotes, induced specific delayed-hypersensitivity reactions, and generated populations of peritoneal macrophages capable of killing amastigotes. Vaccination resulted in no harmful effects, since these antigen neither exacerbated preexisting Leishmania infection nor impeded the formation of antibodies to other antigens administered concomitantly.

Documentos Relacionados

• Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.
• Genetic complementation of defects in vaccine-induced immunity against Schistosoma mansoni in P- and A-strain inbred mice.
• Pretreatment with Recombinant Flt3 Ligand Partially Protects against Progressive Cutaneous Leishmaniasis in Susceptible BALB/c Mice
• Experimental production of actinomycetoma in BALB/c mice.
• Gastrointestinal microecology of BALB/c nude mice.